Urinary T Cell Biomarker for Prediction in ANCA Glomerulonephritis

Glomerulonephritis Acute Clinical Trial

Official title: Phenotype of Urinary CD4+ T Cells as Biomarkers for Prediction of Outcome in ANCA Glomerulonephritis

Status Active, not recruiting

Clinical Trial Summary

Urinary T lymphocytes may be predictive for clinical outcome in patients with ANCA associated glomerulonephritis (ANCA GN). The investigators hypothesize that the amount of CD4+ effector/memory T cells in urine at time of diagnosis predicts the outcome of patients with active ANCA GN after 6 months of therapy. In a prospective, six-months follow-up study patients' urine will be analysed by flow cytometry every 60 days (+/- 10d). Treatment will be performed to the discretion of the treating clinician. After 6 months of treatment response will be determined as either complete response or partial response.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Glomerulonephritis
• Glomerulonephritis Acute

• NCT number: NCT04320667
• Study type: Observational
• Source: Charite University, Berlin, Germany
• Status: Active, not recruiting
• Start date: November 19, 2019
• Completion date: December 2022